Capricor Therapeutics (CAPR) Stock Forecast & Price Target

Compare

1,031 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CAPR Analyst Ratings

Strong Buy

9 Buy

1 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Capricor

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CAPR Stock 12 Month Forecast

Average Price Target

$30.60

▲(167.95%Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Capricor Therapeutics in the last 3 months. The average price target is $30.60 with a high forecast of $77.00 and a low forecast of $8.00. The average price target represents a 167.95% change from the last price of $11.42.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","21":"$21","40":"$40","59":"$59","78":"$78"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":77,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$77.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,21,40,59,78],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.21,15.347692307692308,20.485384615384614,25.623076923076923,30.760769230769228,35.89846153846153,41.03615384615384,46.17384615384615,51.311538461538454,56.44923076923076,61.586923076923064,66.72461538461538,71.86230769230768,{"y":77,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.21,11.778461538461539,13.346923076923078,14.915384615384617,16.483846153846155,18.052307692307693,19.620769230769234,21.18923076923077,22.75769230769231,24.326153846153847,25.894615384615385,27.463076923076926,29.031538461538464,{"y":30.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.21,10.040000000000001,9.870000000000001,9.700000000000001,9.530000000000001,9.360000000000001,9.190000000000001,9.02,8.85,8.68,8.51,8.34,8.17,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.33,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.68,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.84,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.91,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.57,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.01,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.45,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.38,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.48,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.21,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$77.00

Average Price Target$30.60

Lowest Price Target$8.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$10

Hold

-12.43%

Downside

Reiterated

07/10/25

Capricor Therapeutics' overall score reflects its significant potential due to advancements in drug development and strategic partnerships, particularly for deramiocel. However, persistent financial challenges, particularly profitability and cash flow issues, weigh heavily on the stock's outlook. Technical indicators show mixed signals, and valuation remains speculative with a negative P/E ratio.

Matthew VeneziaAlliance Global Partners

Alliance Global Partners

$20

Buy

75.13%

Upside

Initiated

06/30/25

Capricor Therapeutics initiated with a Buy at Alliance Global PartnersCapricor Therapeutics initiated with a Buy at Alliance Global Partners

Madison ElsaadiB.Riley Financial

B.Riley Financial

$21

Buy

83.89%

Upside

Initiated

06/26/25

Capricor Therapeutics (CAPR) Receives a Buy from B.Riley Financial

Joseph PantginisH.C. Wainwright

H.C. Wainwright

$77

Buy

574.26%

Upside

Reiterated

06/25/25

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Capricor Therapeutics (NASDAQ: CAPR) and Abbott Laboratories (NYSE: ABT)

Catherine NovackJonesTrading

JonesTrading

$40→$29

Buy

153.94%

Upside

Reiterated

06/24/25

Capricor Therapeutics price target lowered to $29 from $40 at JonesResearchCapricor Therapeutics price target lowered to $29 from $40 at JonesResearch

Boobalan PachaiyappanRoth MKM

Roth MKM

$31

Buy

171.45%

Upside

Reiterated

06/24/25

Roth MKM Sticks to Its Buy Rating for Capricor Therapeutics (CAPR)

Jason McCarthyMaxim Group

Maxim Group

$25

Buy

118.91%

Upside

Reiterated

06/24/25

Capricor Therapeutics: Buy Rating Affirmed Amidst Regulatory Clarity and Positive Clinical Data for Deramiocel

Kristen KluskaCantor Fitzgerald

Cantor Fitzgerald

$30

Buy

162.70%

Upside

Reiterated

06/23/25

Capricor Therapeutics (CAPR) Receives a Buy from Cantor Fitzgerald

Leland GershellOppenheimer

Oppenheimer

$43→$22

Buy

92.64%

Upside

Reiterated

06/23/25

Capricor Therapeutics (CAPR) Receives a Buy from Oppenheimer

Dex GenotekAI Firm

AI Firm

$12.5→$8

Hold

-29.95%

Downside

Reiterated

06/21/25

Edward TenthoffPiper Sandler

Piper Sandler

$43

Buy

276.53%

Upside

Reiterated

05/15/25

Capricor Therapeutics (CAPR) Gets a Buy from Piper Sandler

Aydin HuseynovLadenburg Thalmann & Co.

Ladenburg Thalmann & Co.

$48

Buy

320.32%

Upside

Reiterated

03/20/25

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$10

Hold

-12.43%

Downside

Reiterated

07/10/25

Matthew VeneziaAlliance Global Partners

Alliance Global Partners

$20

Buy

75.13%

Upside

Initiated

06/30/25

Capricor Therapeutics initiated with a Buy at Alliance Global PartnersCapricor Therapeutics initiated with a Buy at Alliance Global Partners

Madison ElsaadiB.Riley Financial

B.Riley Financial

$21

Buy

83.89%

Upside

Initiated

06/26/25

Capricor Therapeutics (CAPR) Receives a Buy from B.Riley Financial

Joseph PantginisH.C. Wainwright

H.C. Wainwright

$77

Buy

574.26%

Upside

Reiterated

06/25/25

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Capricor Therapeutics (NASDAQ: CAPR) and Abbott Laboratories (NYSE: ABT)

Catherine NovackJonesTrading

JonesTrading

$40→$29

Buy

153.94%

Upside

Reiterated

06/24/25

Capricor Therapeutics price target lowered to $29 from $40 at JonesResearchCapricor Therapeutics price target lowered to $29 from $40 at JonesResearch

Boobalan PachaiyappanRoth MKM

Roth MKM

$31

Buy

171.45%

Upside

Reiterated

06/24/25

Roth MKM Sticks to Its Buy Rating for Capricor Therapeutics (CAPR)

Jason McCarthyMaxim Group

Maxim Group

$25

Buy

118.91%

Upside

Reiterated

06/24/25

Capricor Therapeutics: Buy Rating Affirmed Amidst Regulatory Clarity and Positive Clinical Data for Deramiocel

Kristen KluskaCantor Fitzgerald

Cantor Fitzgerald

$30

Buy

162.70%

Upside

Reiterated

06/23/25

Capricor Therapeutics (CAPR) Receives a Buy from Cantor Fitzgerald

Leland GershellOppenheimer

Oppenheimer

$43→$22

Buy

92.64%

Upside

Reiterated

06/23/25

Capricor Therapeutics (CAPR) Receives a Buy from Oppenheimer

Dex GenotekAI Firm

AI Firm

$12.5→$8

Hold

-29.95%

Downside

Reiterated

06/21/25

Edward TenthoffPiper Sandler

Piper Sandler

$43

Buy

276.53%

Upside

Reiterated

05/15/25

Capricor Therapeutics (CAPR) Gets a Buy from Piper Sandler

Aydin HuseynovLadenburg Thalmann & Co.

Ladenburg Thalmann & Co.

$48

Buy

320.32%

Upside

Reiterated

03/20/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Capricor Therapeutics

1 Month

xxx

Success Rate

7/12 ratings generated profit

Average Return

+23.78%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 58.33% of your transactions generating a profit, with an average return of +23.78% per trade.

3 Months

xxx

Success Rate

5/8 ratings generated profit

Average Return

+62.56%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +62.56% per trade.

1 Year

Kristen KluskaCantor Fitzgerald

Success Rate

6/8 ratings generated profit

Average Return

+52.70%

reiterated a buy rating 18 days ago

Copying Kristen Kluska's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +52.70% per trade.

2 Years

xxx

Success Rate

6/8 ratings generated profit

Average Return

+46.77%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +46.77% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CAPR Analyst Recommendation Trends

Rating

Jan 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CAPR has received 23 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. CAPR average Analyst price target in the past 3 months is 30.60.

Each month's total comprises the sum of three months' worth of ratings.

CAPR Financial Forecast

CAPR Earnings Forecast

Next quarter’s earnings estimate for CAPR is -$0.46 with a range of -$0.53 to -$0.36. The previous quarter’s EPS was -$0.53. CAPR beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.10% of the time in the same period. In the last calendar year CAPR has Outperformed its overall industry.

CAPR Sales Forecast

Next quarter’s sales forecast for CAPR is $1.42M with a range of $0.00 to $5.00M. The previous quarter’s sales results were $0.00. CAPR beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.56% of the time in the same period. In the last calendar year CAPR has Outperformed its overall industry.

CAPR Stock Forecast FAQ

What is CAPR’s average 12-month price target, according to analysts?

Based on analyst ratings, Capricor Therapeutics’s 12-month average price target is 30.60.

What is CAPR’s upside potential, based on the analysts’ average price target?

Capricor Therapeutics has 167.95% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CAPR a Buy, Sell or Hold?

Capricor Therapeutics has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.

What is Capricor Therapeutics’s price target?

The average price target for Capricor Therapeutics is 30.60. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $77.00 ,the lowest forecast is $8.00. The average price target represents 167.95% Increase from the current price of $11.42.

What do analysts say about Capricor Therapeutics?

Capricor Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of CAPR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Capricor Therapeutics (CAPR) Stock Forecast & Price Target

CAPR Analyst Ratings

CAPR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Capricor Therapeutics

CAPR Analyst Recommendation Trends

CAPR Financial Forecast

CAPR Earnings Forecast

CAPR Sales Forecast

CAPR Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts